NeuroMetrix, Inc. (NASDAQ:NURO) is scheduled to be releasing its earnings data before the market opens on Wednesday, October 18th.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings data on Thursday, July 20th. The medical device company reported ($2.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.83) by $0.34. NeuroMetrix had a negative return on equity of 209.56% and a negative net margin of 83.92%. The firm had revenue of $4.31 million during the quarter, compared to analyst estimates of $4.40 million. On average, analysts expect NeuroMetrix to post $-11.20 EPS for the current fiscal year and $-1.62 EPS for the next fiscal year.

NeuroMetrix, Inc. (NASDAQ:NURO) opened at 1.83 on Wednesday. The firm’s market capitalization is $3.40 million. NeuroMetrix, Inc. has a 1-year low of $0.38 and a 1-year high of $4.50. The firm’s 50-day moving average price is $2.01 and its 200 day moving average price is $2.02.

TRADEMARK VIOLATION NOTICE: “NeuroMetrix, Inc. (NURO) Set to Announce Earnings on Wednesday” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/11/neurometrix-inc-nuro-set-to-announce-earnings-on-wednesday.html.

A number of research firms have recently weighed in on NURO. HC Wainwright set a $16.00 target price on NeuroMetrix and gave the company a “buy” rating in a research report on Thursday, June 15th. Zacks Investment Research downgraded NeuroMetrix from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th.

NeuroMetrix Company Profile

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Earnings History for NeuroMetrix (NASDAQ:NURO)

Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.